U.S. stocks rise on Fed cut bets; earnings continue to flow
Director Lynne Parshall of Ionis Pharmaceuticals (NASDAQ:IONS) sold 20,000 shares of common stock on September 2, 2025, for a total of $1,018,297. The timing of this sale is notable as InvestingPro data shows the stock trading near its 52-week high of $62.08, having surged 39% in the past week alone.
The sales were executed in two separate transactions. In the first, 10,750 shares were sold at a weighted average price of $50.42, with prices ranging from $50.0137 to $50.92. The second transaction involved the sale of 9,250 shares at a weighted average price of $51.49, with prices ranging from $51.24 to $51.81.
Following these transactions, Parshall directly owns 66,344 shares of Ionis Pharmaceuticals. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 6, 2025.
In other recent news, Ionis Pharmaceuticals has reported significant developments in its clinical trials and analyst evaluations. The company announced positive topline results from its Phase 3 CORE and CORE2 trials for severe hypertriglyceridemia, demonstrating statistically significant benefits on triglyceride lowering and acute pancreatitis risk reduction. This announcement led to a 32% surge in the company’s stock. Following these results, RBC Capital raised its price target for Ionis Pharmaceuticals to $80, citing the drug’s potential in treating acute pancreatitis, while H.C. Wainwright increased its target to $95 due to strong triglyceride reductions observed in the pivotal studies. Additionally, BMO Capital upgraded Ionis Pharmaceuticals from Market Perform to Outperform, highlighting the promising future of the drug Olezarsen as a potential blockbuster in the US market. Oppenheimer also adjusted its price target to $81, maintaining an Outperform rating, in light of the positive Phase 3 trial results for Tryngolza (olezarsen). These recent developments reflect a growing confidence among analysts in Ionis Pharmaceuticals’ drug pipeline and potential market impact.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.